Beltsville, MD, October 29, 2025- REPROCELL currently offers hypoimmune hiPSC lines with HLA I/II knockouts (B2M/CIITA homozygous double KO) that employ StemEdit gene-editing technology using an alternate to popular research grade caspases. Caspases are specialized enzymes that can be engineered to precisely modify genetic material during gene editing. This approach provides a robust and strategic alternative to patented caspases and helps to navigate intellectual property constraints while [...]
This is an abstract of the document. To keep reading, click here and get access to the original version.